nodes	percent_of_prediction	percent_of_DWPC	metapath
Thiotepa—Alkylating Activity—Mitomycin—urinary bladder cancer	0.871	1	CiPCiCtD
Thiotepa—CYP2B6—Cisplatin—urinary bladder cancer	0.0136	0.459	CbGbCtD
Thiotepa—CYP2B6—Doxorubicin—urinary bladder cancer	0.00909	0.308	CbGbCtD
Thiotepa—CYP3A4—Etoposide—urinary bladder cancer	0.00409	0.139	CbGbCtD
Thiotepa—CYP3A4—Doxorubicin—urinary bladder cancer	0.00279	0.0945	CbGbCtD
Thiotepa—CYP2B6—Fatty acids—CYP4B1—urinary bladder cancer	0.000153	0.0968	CbGpPWpGaD
Thiotepa—CYP3A4—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.000128	0.0808	CbGpPWpGaD
Thiotepa—CYP2B6—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.000106	0.0666	CbGpPWpGaD
Thiotepa—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	7.97e-05	0.0503	CbGpPWpGaD
Thiotepa—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	6.69e-05	0.0422	CbGpPWpGaD
Thiotepa—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	5.91e-05	0.0373	CbGpPWpGaD
Thiotepa—Epistaxis—Methotrexate—urinary bladder cancer	5.87e-05	0.000602	CcSEcCtD
Thiotepa—Pneumonia—Epirubicin—urinary bladder cancer	5.86e-05	0.000601	CcSEcCtD
Thiotepa—Infestation NOS—Epirubicin—urinary bladder cancer	5.83e-05	0.000598	CcSEcCtD
Thiotepa—Infestation—Epirubicin—urinary bladder cancer	5.83e-05	0.000598	CcSEcCtD
Thiotepa—Agranulocytosis—Methotrexate—urinary bladder cancer	5.81e-05	0.000596	CcSEcCtD
Thiotepa—Decreased appetite—Etoposide—urinary bladder cancer	5.76e-05	0.000591	CcSEcCtD
Thiotepa—Pancytopenia—Doxorubicin—urinary bladder cancer	5.74e-05	0.000589	CcSEcCtD
Thiotepa—Renal failure—Epirubicin—urinary bladder cancer	5.73e-05	0.000588	CcSEcCtD
Thiotepa—Gastrointestinal disorder—Etoposide—urinary bladder cancer	5.72e-05	0.000587	CcSEcCtD
Thiotepa—Body temperature increased—Cisplatin—urinary bladder cancer	5.72e-05	0.000587	CcSEcCtD
Thiotepa—Fatigue—Etoposide—urinary bladder cancer	5.72e-05	0.000586	CcSEcCtD
Thiotepa—Jaundice—Epirubicin—urinary bladder cancer	5.68e-05	0.000583	CcSEcCtD
Thiotepa—Stomatitis—Epirubicin—urinary bladder cancer	5.68e-05	0.000583	CcSEcCtD
Thiotepa—Pain—Etoposide—urinary bladder cancer	5.67e-05	0.000582	CcSEcCtD
Thiotepa—Constipation—Etoposide—urinary bladder cancer	5.67e-05	0.000582	CcSEcCtD
Thiotepa—Conjunctivitis—Epirubicin—urinary bladder cancer	5.66e-05	0.000581	CcSEcCtD
Thiotepa—Dysuria—Doxorubicin—urinary bladder cancer	5.65e-05	0.00058	CcSEcCtD
Thiotepa—Hypersensitivity—Fluorouracil—urinary bladder cancer	5.62e-05	0.000577	CcSEcCtD
Thiotepa—Haemoglobin—Methotrexate—urinary bladder cancer	5.62e-05	0.000576	CcSEcCtD
Thiotepa—Haemorrhage—Methotrexate—urinary bladder cancer	5.59e-05	0.000573	CcSEcCtD
Thiotepa—Asthenia—Gemcitabine—urinary bladder cancer	5.57e-05	0.000571	CcSEcCtD
Thiotepa—Haematuria—Epirubicin—urinary bladder cancer	5.56e-05	0.00057	CcSEcCtD
Thiotepa—Urinary tract disorder—Methotrexate—urinary bladder cancer	5.52e-05	0.000566	CcSEcCtD
Thiotepa—Hepatobiliary disease—Epirubicin—urinary bladder cancer	5.51e-05	0.000565	CcSEcCtD
Thiotepa—Weight increased—Doxorubicin—urinary bladder cancer	5.5e-05	0.000565	CcSEcCtD
Thiotepa—Epistaxis—Epirubicin—urinary bladder cancer	5.5e-05	0.000564	CcSEcCtD
Thiotepa—Pruritus—Gemcitabine—urinary bladder cancer	5.49e-05	0.000564	CcSEcCtD
Thiotepa—Urethral disorder—Methotrexate—urinary bladder cancer	5.48e-05	0.000562	CcSEcCtD
Thiotepa—Feeling abnormal—Etoposide—urinary bladder cancer	5.46e-05	0.00056	CcSEcCtD
Thiotepa—Hyperglycaemia—Doxorubicin—urinary bladder cancer	5.45e-05	0.00056	CcSEcCtD
Thiotepa—Agranulocytosis—Epirubicin—urinary bladder cancer	5.44e-05	0.000558	CcSEcCtD
Thiotepa—Pneumonia—Doxorubicin—urinary bladder cancer	5.42e-05	0.000556	CcSEcCtD
Thiotepa—Gastrointestinal pain—Etoposide—urinary bladder cancer	5.42e-05	0.000556	CcSEcCtD
Thiotepa—Pruritus—Fluorouracil—urinary bladder cancer	5.4e-05	0.000554	CcSEcCtD
Thiotepa—Infestation—Doxorubicin—urinary bladder cancer	5.39e-05	0.000553	CcSEcCtD
Thiotepa—Infestation NOS—Doxorubicin—urinary bladder cancer	5.39e-05	0.000553	CcSEcCtD
Thiotepa—Hypersensitivity—Cisplatin—urinary bladder cancer	5.33e-05	0.000547	CcSEcCtD
Thiotepa—Diarrhoea—Gemcitabine—urinary bladder cancer	5.31e-05	0.000545	CcSEcCtD
Thiotepa—Renal failure—Doxorubicin—urinary bladder cancer	5.3e-05	0.000544	CcSEcCtD
Thiotepa—Urticaria—Etoposide—urinary bladder cancer	5.27e-05	0.00054	CcSEcCtD
Thiotepa—Haemoglobin—Epirubicin—urinary bladder cancer	5.26e-05	0.000539	CcSEcCtD
Thiotepa—Stomatitis—Doxorubicin—urinary bladder cancer	5.26e-05	0.000539	CcSEcCtD
Thiotepa—Jaundice—Doxorubicin—urinary bladder cancer	5.26e-05	0.000539	CcSEcCtD
Thiotepa—Abdominal pain—Etoposide—urinary bladder cancer	5.24e-05	0.000538	CcSEcCtD
Thiotepa—Body temperature increased—Etoposide—urinary bladder cancer	5.24e-05	0.000538	CcSEcCtD
Thiotepa—Conjunctivitis—Doxorubicin—urinary bladder cancer	5.24e-05	0.000538	CcSEcCtD
Thiotepa—Haemorrhage—Epirubicin—urinary bladder cancer	5.23e-05	0.000537	CcSEcCtD
Thiotepa—Eye disorder—Methotrexate—urinary bladder cancer	5.22e-05	0.000536	CcSEcCtD
Thiotepa—Diarrhoea—Fluorouracil—urinary bladder cancer	5.22e-05	0.000536	CcSEcCtD
Thiotepa—Tinnitus—Methotrexate—urinary bladder cancer	5.21e-05	0.000535	CcSEcCtD
Thiotepa—Asthenia—Cisplatin—urinary bladder cancer	5.19e-05	0.000533	CcSEcCtD
Thiotepa—Cardiac disorder—Methotrexate—urinary bladder cancer	5.19e-05	0.000532	CcSEcCtD
Thiotepa—Urinary tract disorder—Epirubicin—urinary bladder cancer	5.17e-05	0.00053	CcSEcCtD
Thiotepa—Haematuria—Doxorubicin—urinary bladder cancer	5.14e-05	0.000527	CcSEcCtD
Thiotepa—Connective tissue disorder—Epirubicin—urinary bladder cancer	5.14e-05	0.000527	CcSEcCtD
Thiotepa—Urethral disorder—Epirubicin—urinary bladder cancer	5.13e-05	0.000526	CcSEcCtD
Thiotepa—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	5.1e-05	0.000523	CcSEcCtD
Thiotepa—Epistaxis—Doxorubicin—urinary bladder cancer	5.09e-05	0.000522	CcSEcCtD
Thiotepa—Angiopathy—Methotrexate—urinary bladder cancer	5.07e-05	0.00052	CcSEcCtD
Thiotepa—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	5.06e-05	0.0319	CbGpPWpGaD
Thiotepa—Immune system disorder—Methotrexate—urinary bladder cancer	5.05e-05	0.000518	CcSEcCtD
Thiotepa—Dizziness—Fluorouracil—urinary bladder cancer	5.05e-05	0.000518	CcSEcCtD
Thiotepa—Mediastinal disorder—Methotrexate—urinary bladder cancer	5.04e-05	0.000517	CcSEcCtD
Thiotepa—Agranulocytosis—Doxorubicin—urinary bladder cancer	5.03e-05	0.000516	CcSEcCtD
Thiotepa—Chills—Methotrexate—urinary bladder cancer	5.02e-05	0.000515	CcSEcCtD
Thiotepa—CYP2B6—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	4.99e-05	0.0315	CbGpPWpGaD
Thiotepa—Diarrhoea—Cisplatin—urinary bladder cancer	4.95e-05	0.000508	CcSEcCtD
Thiotepa—Alopecia—Methotrexate—urinary bladder cancer	4.94e-05	0.000507	CcSEcCtD
Thiotepa—Vomiting—Gemcitabine—urinary bladder cancer	4.94e-05	0.000506	CcSEcCtD
Thiotepa—Mental disorder—Methotrexate—urinary bladder cancer	4.9e-05	0.000502	CcSEcCtD
Thiotepa—Rash—Gemcitabine—urinary bladder cancer	4.9e-05	0.000502	CcSEcCtD
Thiotepa—Dermatitis—Gemcitabine—urinary bladder cancer	4.89e-05	0.000502	CcSEcCtD
Thiotepa—Eye disorder—Epirubicin—urinary bladder cancer	4.89e-05	0.000501	CcSEcCtD
Thiotepa—Hypersensitivity—Etoposide—urinary bladder cancer	4.88e-05	0.000501	CcSEcCtD
Thiotepa—Tinnitus—Epirubicin—urinary bladder cancer	4.88e-05	0.0005	CcSEcCtD
Thiotepa—Erythema—Methotrexate—urinary bladder cancer	4.87e-05	0.000499	CcSEcCtD
Thiotepa—Malnutrition—Methotrexate—urinary bladder cancer	4.87e-05	0.000499	CcSEcCtD
Thiotepa—Haemoglobin—Doxorubicin—urinary bladder cancer	4.86e-05	0.000499	CcSEcCtD
Thiotepa—Headache—Gemcitabine—urinary bladder cancer	4.86e-05	0.000499	CcSEcCtD
Thiotepa—Cardiac disorder—Epirubicin—urinary bladder cancer	4.85e-05	0.000498	CcSEcCtD
Thiotepa—Vomiting—Fluorouracil—urinary bladder cancer	4.85e-05	0.000498	CcSEcCtD
Thiotepa—Haemorrhage—Doxorubicin—urinary bladder cancer	4.84e-05	0.000497	CcSEcCtD
Thiotepa—Rash—Fluorouracil—urinary bladder cancer	4.81e-05	0.000494	CcSEcCtD
Thiotepa—Dermatitis—Fluorouracil—urinary bladder cancer	4.81e-05	0.000493	CcSEcCtD
Thiotepa—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	4.8e-05	0.0303	CbGpPWpGaD
Thiotepa—Headache—Fluorouracil—urinary bladder cancer	4.78e-05	0.000491	CcSEcCtD
Thiotepa—Urinary tract disorder—Doxorubicin—urinary bladder cancer	4.78e-05	0.00049	CcSEcCtD
Thiotepa—Asthenia—Etoposide—urinary bladder cancer	4.76e-05	0.000488	CcSEcCtD
Thiotepa—Connective tissue disorder—Doxorubicin—urinary bladder cancer	4.76e-05	0.000488	CcSEcCtD
Thiotepa—Angiopathy—Epirubicin—urinary bladder cancer	4.75e-05	0.000487	CcSEcCtD
Thiotepa—Urethral disorder—Doxorubicin—urinary bladder cancer	4.74e-05	0.000487	CcSEcCtD
Thiotepa—Immune system disorder—Epirubicin—urinary bladder cancer	4.72e-05	0.000485	CcSEcCtD
Thiotepa—Mediastinal disorder—Epirubicin—urinary bladder cancer	4.71e-05	0.000484	CcSEcCtD
Thiotepa—Back pain—Methotrexate—urinary bladder cancer	4.71e-05	0.000483	CcSEcCtD
Thiotepa—Chills—Epirubicin—urinary bladder cancer	4.69e-05	0.000481	CcSEcCtD
Thiotepa—Pruritus—Etoposide—urinary bladder cancer	4.69e-05	0.000481	CcSEcCtD
Thiotepa—Arrhythmia—Epirubicin—urinary bladder cancer	4.67e-05	0.000479	CcSEcCtD
Thiotepa—Alopecia—Epirubicin—urinary bladder cancer	4.62e-05	0.000474	CcSEcCtD
Thiotepa—Nausea—Gemcitabine—urinary bladder cancer	4.61e-05	0.000473	CcSEcCtD
Thiotepa—Vomiting—Cisplatin—urinary bladder cancer	4.6e-05	0.000472	CcSEcCtD
Thiotepa—Vision blurred—Methotrexate—urinary bladder cancer	4.59e-05	0.00047	CcSEcCtD
Thiotepa—Mental disorder—Epirubicin—urinary bladder cancer	4.58e-05	0.00047	CcSEcCtD
Thiotepa—Rash—Cisplatin—urinary bladder cancer	4.56e-05	0.000468	CcSEcCtD
Thiotepa—Dermatitis—Cisplatin—urinary bladder cancer	4.56e-05	0.000468	CcSEcCtD
Thiotepa—Erythema—Epirubicin—urinary bladder cancer	4.55e-05	0.000467	CcSEcCtD
Thiotepa—Malnutrition—Epirubicin—urinary bladder cancer	4.55e-05	0.000467	CcSEcCtD
Thiotepa—Diarrhoea—Etoposide—urinary bladder cancer	4.54e-05	0.000465	CcSEcCtD
Thiotepa—Nausea—Fluorouracil—urinary bladder cancer	4.53e-05	0.000465	CcSEcCtD
Thiotepa—Eye disorder—Doxorubicin—urinary bladder cancer	4.52e-05	0.000464	CcSEcCtD
Thiotepa—Tinnitus—Doxorubicin—urinary bladder cancer	4.51e-05	0.000463	CcSEcCtD
Thiotepa—Anaemia—Methotrexate—urinary bladder cancer	4.5e-05	0.000461	CcSEcCtD
Thiotepa—Cardiac disorder—Doxorubicin—urinary bladder cancer	4.49e-05	0.000461	CcSEcCtD
Thiotepa—Tension—Epirubicin—urinary bladder cancer	4.47e-05	0.000458	CcSEcCtD
Thiotepa—Nervousness—Epirubicin—urinary bladder cancer	4.42e-05	0.000454	CcSEcCtD
Thiotepa—Back pain—Epirubicin—urinary bladder cancer	4.4e-05	0.000452	CcSEcCtD
Thiotepa—Angiopathy—Doxorubicin—urinary bladder cancer	4.39e-05	0.00045	CcSEcCtD
Thiotepa—Dizziness—Etoposide—urinary bladder cancer	4.38e-05	0.00045	CcSEcCtD
Thiotepa—Immune system disorder—Doxorubicin—urinary bladder cancer	4.37e-05	0.000448	CcSEcCtD
Thiotepa—Mediastinal disorder—Doxorubicin—urinary bladder cancer	4.36e-05	0.000447	CcSEcCtD
Thiotepa—Leukopenia—Methotrexate—urinary bladder cancer	4.36e-05	0.000447	CcSEcCtD
Thiotepa—Chills—Doxorubicin—urinary bladder cancer	4.34e-05	0.000446	CcSEcCtD
Thiotepa—Arrhythmia—Doxorubicin—urinary bladder cancer	4.32e-05	0.000444	CcSEcCtD
Thiotepa—Nausea—Cisplatin—urinary bladder cancer	4.3e-05	0.000441	CcSEcCtD
Thiotepa—Vision blurred—Epirubicin—urinary bladder cancer	4.29e-05	0.00044	CcSEcCtD
Thiotepa—Alopecia—Doxorubicin—urinary bladder cancer	4.28e-05	0.000439	CcSEcCtD
Thiotepa—Cough—Methotrexate—urinary bladder cancer	4.25e-05	0.000436	CcSEcCtD
Thiotepa—Mental disorder—Doxorubicin—urinary bladder cancer	4.24e-05	0.000435	CcSEcCtD
Thiotepa—Convulsion—Methotrexate—urinary bladder cancer	4.22e-05	0.000432	CcSEcCtD
Thiotepa—Vomiting—Etoposide—urinary bladder cancer	4.22e-05	0.000432	CcSEcCtD
Thiotepa—Malnutrition—Doxorubicin—urinary bladder cancer	4.21e-05	0.000432	CcSEcCtD
Thiotepa—Erythema—Doxorubicin—urinary bladder cancer	4.21e-05	0.000432	CcSEcCtD
Thiotepa—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	4.21e-05	0.0266	CbGpPWpGaD
Thiotepa—Anaemia—Epirubicin—urinary bladder cancer	4.21e-05	0.000432	CcSEcCtD
Thiotepa—Agitation—Epirubicin—urinary bladder cancer	4.18e-05	0.000429	CcSEcCtD
Thiotepa—Rash—Etoposide—urinary bladder cancer	4.18e-05	0.000429	CcSEcCtD
Thiotepa—Dermatitis—Etoposide—urinary bladder cancer	4.18e-05	0.000428	CcSEcCtD
Thiotepa—Headache—Etoposide—urinary bladder cancer	4.15e-05	0.000426	CcSEcCtD
Thiotepa—Arthralgia—Methotrexate—urinary bladder cancer	4.14e-05	0.000425	CcSEcCtD
Thiotepa—Myalgia—Methotrexate—urinary bladder cancer	4.14e-05	0.000425	CcSEcCtD
Thiotepa—Tension—Doxorubicin—urinary bladder cancer	4.13e-05	0.000424	CcSEcCtD
Thiotepa—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	4.11e-05	0.000422	CcSEcCtD
Thiotepa—CYP2B6—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	4.1e-05	0.0259	CbGpPWpGaD
Thiotepa—Nervousness—Doxorubicin—urinary bladder cancer	4.09e-05	0.00042	CcSEcCtD
Thiotepa—CYP2B6—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	4.08e-05	0.0258	CbGpPWpGaD
Thiotepa—Leukopenia—Epirubicin—urinary bladder cancer	4.08e-05	0.000418	CcSEcCtD
Thiotepa—Back pain—Doxorubicin—urinary bladder cancer	4.08e-05	0.000418	CcSEcCtD
Thiotepa—Confusional state—Methotrexate—urinary bladder cancer	4e-05	0.000411	CcSEcCtD
Thiotepa—Cough—Epirubicin—urinary bladder cancer	3.97e-05	0.000408	CcSEcCtD
Thiotepa—Vision blurred—Doxorubicin—urinary bladder cancer	3.97e-05	0.000407	CcSEcCtD
Thiotepa—Convulsion—Epirubicin—urinary bladder cancer	3.95e-05	0.000405	CcSEcCtD
Thiotepa—Infection—Methotrexate—urinary bladder cancer	3.95e-05	0.000405	CcSEcCtD
Thiotepa—Nausea—Etoposide—urinary bladder cancer	3.94e-05	0.000404	CcSEcCtD
Thiotepa—Hypertension—Epirubicin—urinary bladder cancer	3.93e-05	0.000403	CcSEcCtD
Thiotepa—Nervous system disorder—Methotrexate—urinary bladder cancer	3.89e-05	0.0004	CcSEcCtD
Thiotepa—Anaemia—Doxorubicin—urinary bladder cancer	3.89e-05	0.0004	CcSEcCtD
Thiotepa—Thrombocytopenia—Methotrexate—urinary bladder cancer	3.89e-05	0.000399	CcSEcCtD
Thiotepa—Myalgia—Epirubicin—urinary bladder cancer	3.88e-05	0.000398	CcSEcCtD
Thiotepa—Arthralgia—Epirubicin—urinary bladder cancer	3.88e-05	0.000398	CcSEcCtD
Thiotepa—Agitation—Doxorubicin—urinary bladder cancer	3.87e-05	0.000397	CcSEcCtD
Thiotepa—Anxiety—Epirubicin—urinary bladder cancer	3.86e-05	0.000396	CcSEcCtD
Thiotepa—Skin disorder—Methotrexate—urinary bladder cancer	3.86e-05	0.000396	CcSEcCtD
Thiotepa—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	3.85e-05	0.000395	CcSEcCtD
Thiotepa—Anorexia—Methotrexate—urinary bladder cancer	3.79e-05	0.000388	CcSEcCtD
Thiotepa—Leukopenia—Doxorubicin—urinary bladder cancer	3.77e-05	0.000387	CcSEcCtD
Thiotepa—Confusional state—Epirubicin—urinary bladder cancer	3.75e-05	0.000384	CcSEcCtD
Thiotepa—Infection—Epirubicin—urinary bladder cancer	3.69e-05	0.000379	CcSEcCtD
Thiotepa—Cough—Doxorubicin—urinary bladder cancer	3.68e-05	0.000377	CcSEcCtD
Thiotepa—Convulsion—Doxorubicin—urinary bladder cancer	3.65e-05	0.000374	CcSEcCtD
Thiotepa—Nervous system disorder—Epirubicin—urinary bladder cancer	3.64e-05	0.000374	CcSEcCtD
Thiotepa—Thrombocytopenia—Epirubicin—urinary bladder cancer	3.64e-05	0.000373	CcSEcCtD
Thiotepa—Hypertension—Doxorubicin—urinary bladder cancer	3.64e-05	0.000373	CcSEcCtD
Thiotepa—Tachycardia—Epirubicin—urinary bladder cancer	3.63e-05	0.000372	CcSEcCtD
Thiotepa—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	3.62e-05	0.0229	CbGpPWpGaD
Thiotepa—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	3.62e-05	0.000371	CcSEcCtD
Thiotepa—Skin disorder—Epirubicin—urinary bladder cancer	3.61e-05	0.00037	CcSEcCtD
Thiotepa—Myalgia—Doxorubicin—urinary bladder cancer	3.59e-05	0.000368	CcSEcCtD
Thiotepa—Arthralgia—Doxorubicin—urinary bladder cancer	3.59e-05	0.000368	CcSEcCtD
Thiotepa—Anxiety—Doxorubicin—urinary bladder cancer	3.57e-05	0.000367	CcSEcCtD
Thiotepa—Paraesthesia—Methotrexate—urinary bladder cancer	3.57e-05	0.000366	CcSEcCtD
Thiotepa—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	3.56e-05	0.000365	CcSEcCtD
Thiotepa—Anorexia—Epirubicin—urinary bladder cancer	3.54e-05	0.000363	CcSEcCtD
Thiotepa—Somnolence—Methotrexate—urinary bladder cancer	3.53e-05	0.000362	CcSEcCtD
Thiotepa—Dyspepsia—Methotrexate—urinary bladder cancer	3.5e-05	0.000359	CcSEcCtD
Thiotepa—Confusional state—Doxorubicin—urinary bladder cancer	3.47e-05	0.000356	CcSEcCtD
Thiotepa—Decreased appetite—Methotrexate—urinary bladder cancer	3.45e-05	0.000354	CcSEcCtD
Thiotepa—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	3.43e-05	0.000352	CcSEcCtD
Thiotepa—Fatigue—Methotrexate—urinary bladder cancer	3.42e-05	0.000351	CcSEcCtD
Thiotepa—Infection—Doxorubicin—urinary bladder cancer	3.42e-05	0.00035	CcSEcCtD
Thiotepa—Pain—Methotrexate—urinary bladder cancer	3.4e-05	0.000348	CcSEcCtD
Thiotepa—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	3.39e-05	0.000347	CcSEcCtD
Thiotepa—Nervous system disorder—Doxorubicin—urinary bladder cancer	3.37e-05	0.000346	CcSEcCtD
Thiotepa—Thrombocytopenia—Doxorubicin—urinary bladder cancer	3.37e-05	0.000345	CcSEcCtD
Thiotepa—Tachycardia—Doxorubicin—urinary bladder cancer	3.36e-05	0.000344	CcSEcCtD
Thiotepa—Skin disorder—Doxorubicin—urinary bladder cancer	3.34e-05	0.000343	CcSEcCtD
Thiotepa—Paraesthesia—Epirubicin—urinary bladder cancer	3.34e-05	0.000342	CcSEcCtD
Thiotepa—Somnolence—Epirubicin—urinary bladder cancer	3.3e-05	0.000339	CcSEcCtD
Thiotepa—Anorexia—Doxorubicin—urinary bladder cancer	3.28e-05	0.000336	CcSEcCtD
Thiotepa—Feeling abnormal—Methotrexate—urinary bladder cancer	3.27e-05	0.000336	CcSEcCtD
Thiotepa—Dyspepsia—Epirubicin—urinary bladder cancer	3.27e-05	0.000336	CcSEcCtD
Thiotepa—Gastrointestinal pain—Methotrexate—urinary bladder cancer	3.25e-05	0.000333	CcSEcCtD
Thiotepa—Decreased appetite—Epirubicin—urinary bladder cancer	3.23e-05	0.000331	CcSEcCtD
Thiotepa—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	3.21e-05	0.000329	CcSEcCtD
Thiotepa—Fatigue—Epirubicin—urinary bladder cancer	3.2e-05	0.000329	CcSEcCtD
Thiotepa—Constipation—Epirubicin—urinary bladder cancer	3.18e-05	0.000326	CcSEcCtD
Thiotepa—Pain—Epirubicin—urinary bladder cancer	3.18e-05	0.000326	CcSEcCtD
Thiotepa—Urticaria—Methotrexate—urinary bladder cancer	3.15e-05	0.000324	CcSEcCtD
Thiotepa—Abdominal pain—Methotrexate—urinary bladder cancer	3.14e-05	0.000322	CcSEcCtD
Thiotepa—Body temperature increased—Methotrexate—urinary bladder cancer	3.14e-05	0.000322	CcSEcCtD
Thiotepa—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	3.13e-05	0.000321	CcSEcCtD
Thiotepa—Paraesthesia—Doxorubicin—urinary bladder cancer	3.09e-05	0.000317	CcSEcCtD
Thiotepa—Feeling abnormal—Epirubicin—urinary bladder cancer	3.06e-05	0.000314	CcSEcCtD
Thiotepa—Somnolence—Doxorubicin—urinary bladder cancer	3.06e-05	0.000314	CcSEcCtD
Thiotepa—Gastrointestinal pain—Epirubicin—urinary bladder cancer	3.04e-05	0.000312	CcSEcCtD
Thiotepa—Dyspepsia—Doxorubicin—urinary bladder cancer	3.03e-05	0.000311	CcSEcCtD
Thiotepa—Decreased appetite—Doxorubicin—urinary bladder cancer	2.99e-05	0.000307	CcSEcCtD
Thiotepa—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	2.97e-05	0.000305	CcSEcCtD
Thiotepa—Fatigue—Doxorubicin—urinary bladder cancer	2.96e-05	0.000304	CcSEcCtD
Thiotepa—Urticaria—Epirubicin—urinary bladder cancer	2.95e-05	0.000303	CcSEcCtD
Thiotepa—Constipation—Doxorubicin—urinary bladder cancer	2.94e-05	0.000302	CcSEcCtD
Thiotepa—Pain—Doxorubicin—urinary bladder cancer	2.94e-05	0.000302	CcSEcCtD
Thiotepa—Body temperature increased—Epirubicin—urinary bladder cancer	2.94e-05	0.000301	CcSEcCtD
Thiotepa—Abdominal pain—Epirubicin—urinary bladder cancer	2.94e-05	0.000301	CcSEcCtD
Thiotepa—Hypersensitivity—Methotrexate—urinary bladder cancer	2.93e-05	0.0003	CcSEcCtD
Thiotepa—Asthenia—Methotrexate—urinary bladder cancer	2.85e-05	0.000292	CcSEcCtD
Thiotepa—Feeling abnormal—Doxorubicin—urinary bladder cancer	2.83e-05	0.000291	CcSEcCtD
Thiotepa—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	2.81e-05	0.000288	CcSEcCtD
Thiotepa—Pruritus—Methotrexate—urinary bladder cancer	2.81e-05	0.000288	CcSEcCtD
Thiotepa—CYP2B6—Biological oxidations—GSTZ1—urinary bladder cancer	2.79e-05	0.0176	CbGpPWpGaD
Thiotepa—CYP2B6—Metapathway biotransformation—GSTZ1—urinary bladder cancer	2.75e-05	0.0174	CbGpPWpGaD
Thiotepa—Hypersensitivity—Epirubicin—urinary bladder cancer	2.74e-05	0.000281	CcSEcCtD
Thiotepa—Urticaria—Doxorubicin—urinary bladder cancer	2.73e-05	0.00028	CcSEcCtD
Thiotepa—Abdominal pain—Doxorubicin—urinary bladder cancer	2.72e-05	0.000279	CcSEcCtD
Thiotepa—Body temperature increased—Doxorubicin—urinary bladder cancer	2.72e-05	0.000279	CcSEcCtD
Thiotepa—Diarrhoea—Methotrexate—urinary bladder cancer	2.72e-05	0.000279	CcSEcCtD
Thiotepa—Asthenia—Epirubicin—urinary bladder cancer	2.67e-05	0.000274	CcSEcCtD
Thiotepa—CYP2B6—Biological oxidations—GSTO2—urinary bladder cancer	2.64e-05	0.0167	CbGpPWpGaD
Thiotepa—CYP2B6—Biological oxidations—NAT1—urinary bladder cancer	2.64e-05	0.0167	CbGpPWpGaD
Thiotepa—Pruritus—Epirubicin—urinary bladder cancer	2.63e-05	0.00027	CcSEcCtD
Thiotepa—Dizziness—Methotrexate—urinary bladder cancer	2.63e-05	0.000269	CcSEcCtD
Thiotepa—CYP2B6—Metapathway biotransformation—GSTO2—urinary bladder cancer	2.61e-05	0.0165	CbGpPWpGaD
Thiotepa—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	2.58e-05	0.0163	CbGpPWpGaD
Thiotepa—Diarrhoea—Epirubicin—urinary bladder cancer	2.54e-05	0.000261	CcSEcCtD
Thiotepa—Hypersensitivity—Doxorubicin—urinary bladder cancer	2.53e-05	0.00026	CcSEcCtD
Thiotepa—Vomiting—Methotrexate—urinary bladder cancer	2.52e-05	0.000259	CcSEcCtD
Thiotepa—Rash—Methotrexate—urinary bladder cancer	2.5e-05	0.000257	CcSEcCtD
Thiotepa—Dermatitis—Methotrexate—urinary bladder cancer	2.5e-05	0.000257	CcSEcCtD
Thiotepa—Headache—Methotrexate—urinary bladder cancer	2.49e-05	0.000255	CcSEcCtD
Thiotepa—Asthenia—Doxorubicin—urinary bladder cancer	2.47e-05	0.000253	CcSEcCtD
Thiotepa—Dizziness—Epirubicin—urinary bladder cancer	2.46e-05	0.000252	CcSEcCtD
Thiotepa—Pruritus—Doxorubicin—urinary bladder cancer	2.43e-05	0.00025	CcSEcCtD
Thiotepa—CYP2B6—Biological oxidations—UGT2B7—urinary bladder cancer	2.42e-05	0.0153	CbGpPWpGaD
Thiotepa—CYP2B6—Metapathway biotransformation—UGT2B7—urinary bladder cancer	2.39e-05	0.0151	CbGpPWpGaD
Thiotepa—Vomiting—Epirubicin—urinary bladder cancer	2.36e-05	0.000242	CcSEcCtD
Thiotepa—Nausea—Methotrexate—urinary bladder cancer	2.36e-05	0.000242	CcSEcCtD
Thiotepa—Diarrhoea—Doxorubicin—urinary bladder cancer	2.35e-05	0.000241	CcSEcCtD
Thiotepa—Rash—Epirubicin—urinary bladder cancer	2.34e-05	0.00024	CcSEcCtD
Thiotepa—Dermatitis—Epirubicin—urinary bladder cancer	2.34e-05	0.00024	CcSEcCtD
Thiotepa—Headache—Epirubicin—urinary bladder cancer	2.33e-05	0.000239	CcSEcCtD
Thiotepa—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	2.3e-05	0.0145	CbGpPWpGaD
Thiotepa—Dizziness—Doxorubicin—urinary bladder cancer	2.27e-05	0.000233	CcSEcCtD
Thiotepa—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	2.27e-05	0.0143	CbGpPWpGaD
Thiotepa—Nausea—Epirubicin—urinary bladder cancer	2.21e-05	0.000226	CcSEcCtD
Thiotepa—Vomiting—Doxorubicin—urinary bladder cancer	2.19e-05	0.000224	CcSEcCtD
Thiotepa—CYP2B6—Biological oxidations—CYP4B1—urinary bladder cancer	2.18e-05	0.0137	CbGpPWpGaD
Thiotepa—Rash—Doxorubicin—urinary bladder cancer	2.17e-05	0.000222	CcSEcCtD
Thiotepa—Dermatitis—Doxorubicin—urinary bladder cancer	2.17e-05	0.000222	CcSEcCtD
Thiotepa—Headache—Doxorubicin—urinary bladder cancer	2.15e-05	0.000221	CcSEcCtD
Thiotepa—CYP2B6—Metapathway biotransformation—CYP4B1—urinary bladder cancer	2.15e-05	0.0136	CbGpPWpGaD
Thiotepa—Nausea—Doxorubicin—urinary bladder cancer	2.04e-05	0.00021	CcSEcCtD
Thiotepa—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	1.98e-05	0.0125	CbGpPWpGaD
Thiotepa—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	1.88e-05	0.0118	CbGpPWpGaD
Thiotepa—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	1.86e-05	0.0118	CbGpPWpGaD
Thiotepa—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	1.86e-05	0.0117	CbGpPWpGaD
Thiotepa—CYP2B6—Biological oxidations—NAT2—urinary bladder cancer	1.45e-05	0.00915	CbGpPWpGaD
Thiotepa—CYP2B6—Metapathway biotransformation—NAT2—urinary bladder cancer	1.43e-05	0.00902	CbGpPWpGaD
Thiotepa—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	1.27e-05	0.008	CbGpPWpGaD
Thiotepa—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	1.25e-05	0.00789	CbGpPWpGaD
Thiotepa—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	1.2e-05	0.00759	CbGpPWpGaD
Thiotepa—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	1.2e-05	0.00759	CbGpPWpGaD
Thiotepa—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	1.19e-05	0.00748	CbGpPWpGaD
Thiotepa—CYP2B6—Biological oxidations—HPGDS—urinary bladder cancer	1.16e-05	0.00731	CbGpPWpGaD
Thiotepa—CYP2B6—Biological oxidations—GSTT1—urinary bladder cancer	1.12e-05	0.00709	CbGpPWpGaD
Thiotepa—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	1.1e-05	0.00694	CbGpPWpGaD
Thiotepa—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	1.08e-05	0.00684	CbGpPWpGaD
Thiotepa—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	9.9e-06	0.00625	CbGpPWpGaD
Thiotepa—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	9.76e-06	0.00616	CbGpPWpGaD
Thiotepa—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	8.53e-06	0.00538	CbGpPWpGaD
Thiotepa—CYP2B6—Biological oxidations—GSTP1—urinary bladder cancer	7.79e-06	0.00492	CbGpPWpGaD
Thiotepa—CYP2B6—Metapathway biotransformation—GSTP1—urinary bladder cancer	7.68e-06	0.00485	CbGpPWpGaD
Thiotepa—CYP2B6—Biological oxidations—GSTM1—urinary bladder cancer	7.16e-06	0.00452	CbGpPWpGaD
Thiotepa—CYP2B6—Metapathway biotransformation—GSTM1—urinary bladder cancer	7.06e-06	0.00446	CbGpPWpGaD
Thiotepa—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	6.59e-06	0.00416	CbGpPWpGaD
Thiotepa—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	6.49e-06	0.0041	CbGpPWpGaD
Thiotepa—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	5.26e-06	0.00332	CbGpPWpGaD
Thiotepa—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	5.11e-06	0.00322	CbGpPWpGaD
Thiotepa—CYP2B6—Metabolism—GSTZ1—urinary bladder cancer	4.77e-06	0.00301	CbGpPWpGaD
Thiotepa—CYP2B6—Metabolism—GSTO2—urinary bladder cancer	4.52e-06	0.00286	CbGpPWpGaD
Thiotepa—CYP2B6—Metabolism—NAT1—urinary bladder cancer	4.52e-06	0.00286	CbGpPWpGaD
Thiotepa—CYP2B6—Metabolism—UGT2B7—urinary bladder cancer	4.14e-06	0.00261	CbGpPWpGaD
Thiotepa—CYP2B6—Metabolism—CYP4B1—urinary bladder cancer	3.72e-06	0.00235	CbGpPWpGaD
Thiotepa—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	3.54e-06	0.00223	CbGpPWpGaD
Thiotepa—CYP2B6—Metabolism—SLC19A1—urinary bladder cancer	3.52e-06	0.00222	CbGpPWpGaD
Thiotepa—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.49e-06	0.0022	CbGpPWpGaD
Thiotepa—CYP2B6—Metabolism—PRSS3—urinary bladder cancer	3.43e-06	0.00216	CbGpPWpGaD
Thiotepa—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	3.25e-06	0.00205	CbGpPWpGaD
Thiotepa—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.21e-06	0.00202	CbGpPWpGaD
Thiotepa—CYP2B6—Metabolism—TYMP—urinary bladder cancer	2.74e-06	0.00173	CbGpPWpGaD
Thiotepa—CYP2B6—Metabolism—NAT2—urinary bladder cancer	2.48e-06	0.00156	CbGpPWpGaD
Thiotepa—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	2.17e-06	0.00137	CbGpPWpGaD
Thiotepa—CYP2B6—Metabolism—RRM2—urinary bladder cancer	2.14e-06	0.00135	CbGpPWpGaD
Thiotepa—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	2.06e-06	0.0013	CbGpPWpGaD
Thiotepa—CYP3A4—Metabolism—NAT1—urinary bladder cancer	2.06e-06	0.0013	CbGpPWpGaD
Thiotepa—CYP2B6—Metabolism—HPGDS—urinary bladder cancer	1.98e-06	0.00125	CbGpPWpGaD
Thiotepa—CYP2B6—Metabolism—ENO2—urinary bladder cancer	1.98e-06	0.00125	CbGpPWpGaD
Thiotepa—CYP2B6—Metabolism—GSTT1—urinary bladder cancer	1.92e-06	0.00121	CbGpPWpGaD
Thiotepa—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.88e-06	0.00119	CbGpPWpGaD
Thiotepa—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.69e-06	0.00107	CbGpPWpGaD
Thiotepa—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.6e-06	0.00101	CbGpPWpGaD
Thiotepa—CYP2B6—Metabolism—NQO1—urinary bladder cancer	1.6e-06	0.00101	CbGpPWpGaD
Thiotepa—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.56e-06	0.000983	CbGpPWpGaD
Thiotepa—CYP2B6—Metabolism—GSTP1—urinary bladder cancer	1.33e-06	0.000841	CbGpPWpGaD
Thiotepa—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.25e-06	0.000786	CbGpPWpGaD
Thiotepa—CYP2B6—Metabolism—TYMS—urinary bladder cancer	1.24e-06	0.000782	CbGpPWpGaD
Thiotepa—CYP2B6—Metabolism—GSTM1—urinary bladder cancer	1.22e-06	0.000773	CbGpPWpGaD
Thiotepa—CYP2B6—Metabolism—NCOR1—urinary bladder cancer	1.22e-06	0.000773	CbGpPWpGaD
Thiotepa—CYP2B6—Metabolism—GPX1—urinary bladder cancer	1.17e-06	0.00074	CbGpPWpGaD
Thiotepa—CYP2B6—Metabolism—ERCC2—urinary bladder cancer	1.15e-06	0.000726	CbGpPWpGaD
Thiotepa—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.13e-06	0.000711	CbGpPWpGaD
Thiotepa—CYP2B6—Metabolism—MTHFR—urinary bladder cancer	1.08e-06	0.000683	CbGpPWpGaD
Thiotepa—CYP3A4—Metabolism—RRM2—urinary bladder cancer	9.72e-07	0.000614	CbGpPWpGaD
Thiotepa—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	9e-07	0.000568	CbGpPWpGaD
Thiotepa—CYP3A4—Metabolism—ENO2—urinary bladder cancer	9e-07	0.000568	CbGpPWpGaD
Thiotepa—CYP2B6—Metabolism—PPARG—urinary bladder cancer	8.77e-07	0.000554	CbGpPWpGaD
Thiotepa—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	8.73e-07	0.000551	CbGpPWpGaD
Thiotepa—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	8.43e-07	0.000532	CbGpPWpGaD
Thiotepa—CYP3A4—Metabolism—NQO1—urinary bladder cancer	7.26e-07	0.000458	CbGpPWpGaD
Thiotepa—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	6.9e-07	0.000436	CbGpPWpGaD
Thiotepa—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	6.05e-07	0.000382	CbGpPWpGaD
Thiotepa—CYP2B6—Metabolism—PTEN—urinary bladder cancer	6.02e-07	0.00038	CbGpPWpGaD
Thiotepa—CYP2B6—Metabolism—EP300—urinary bladder cancer	5.74e-07	0.000362	CbGpPWpGaD
Thiotepa—CYP3A4—Metabolism—TYMS—urinary bladder cancer	5.63e-07	0.000355	CbGpPWpGaD
Thiotepa—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	5.56e-07	0.000351	CbGpPWpGaD
Thiotepa—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	5.56e-07	0.000351	CbGpPWpGaD
Thiotepa—CYP3A4—Metabolism—GPX1—urinary bladder cancer	5.33e-07	0.000336	CbGpPWpGaD
Thiotepa—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	5.23e-07	0.00033	CbGpPWpGaD
Thiotepa—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	4.92e-07	0.00031	CbGpPWpGaD
Thiotepa—CYP3A4—Metabolism—PPARG—urinary bladder cancer	3.99e-07	0.000252	CbGpPWpGaD
Thiotepa—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	3.83e-07	0.000242	CbGpPWpGaD
Thiotepa—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.14e-07	0.000198	CbGpPWpGaD
Thiotepa—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.73e-07	0.000173	CbGpPWpGaD
Thiotepa—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.61e-07	0.000165	CbGpPWpGaD
